User Fee Deadline Concerns Emerge As US FDA Buyout Offer Sweetened With Paid Leave

 
• By Sarah Karlin-Smith
  
snail with a stopwatch on its back on yellow background
Project manager eligibility for a new buyout offer at the FDA could lead to slower drug review times. (Shutterstock)

More from US FDA

More from Pathways & Standards